Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Target Price at $15.57

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has been given an average recommendation of “Buy” by the seven ratings firms that are covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $15.57.

A number of brokerages have commented on FULC. Oppenheimer decreased their price objective on Fulcrum Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Tuesday, May 14th. The Goldman Sachs Group raised Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $6.00 to $15.00 in a report on Monday, May 13th. HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Fulcrum Therapeutics in a report on Tuesday, May 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $23.00 target price on shares of Fulcrum Therapeutics in a report on Wednesday, July 10th.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ FULC opened at $8.60 on Thursday. The stock’s fifty day moving average price is $7.36 and its two-hundred day moving average price is $8.14. Fulcrum Therapeutics has a one year low of $3.14 and a one year high of $13.70. The firm has a market cap of $534.49 million, a price-to-earnings ratio of -5.37 and a beta of 2.29.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.01. Fulcrum Therapeutics had a negative return on equity of 40.60% and a negative net margin of 3,470.05%. On average, equities analysts anticipate that Fulcrum Therapeutics will post -1.24 earnings per share for the current fiscal year.

Institutional Trading of Fulcrum Therapeutics

Large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. raised its position in Fulcrum Therapeutics by 66.7% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,916 shares of the company’s stock valued at $112,000 after purchasing an additional 4,766 shares during the last quarter. Capstone Investment Advisors LLC bought a new position in Fulcrum Therapeutics in the fourth quarter valued at about $68,000. SG Americas Securities LLC bought a new position in Fulcrum Therapeutics in the first quarter valued at about $115,000. Vanguard Group Inc. raised its position in Fulcrum Therapeutics by 0.7% in the first quarter. Vanguard Group Inc. now owns 2,538,665 shares of the company’s stock valued at $23,965,000 after purchasing an additional 18,681 shares during the last quarter. Finally, StemPoint Capital LP raised its position in Fulcrum Therapeutics by 8.1% in the first quarter. StemPoint Capital LP now owns 407,108 shares of the company’s stock valued at $3,843,000 after purchasing an additional 30,535 shares during the last quarter. 89.83% of the stock is owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.